Literature DB >> 8772557

The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women.

P Moghetti1, F Tosi, R Castello, C M Magnani, C Negri, E Brun, L Furlani, M Caputo, M Muggeo.   

Abstract

To assess whether androgen excess per se might impair insulin action, insulin sensitivity was measured by a two-step (20 and 80 mU/m2.min) hyperinsulinemic euglycemic clamp combined with indirect calorimetry and tracer glucose infusion in 43 women (13 obese and 30 nonobese) with normal glucose tolerance and clinical evidence of increased androgen action (hirsutism and/or polycystic ovary syndrome) as well as 12 age- and body mass index-matched healthy controls. Hyperandrogenic women were studied basally and after 3-4 months of antiandrogen treatment with 3 different drugs: spironolactone (n = 23), flutamide (n = 10), or the GnRH agonist buserelin (n = 10). Six women given spironolactone were also reexamined after 1 yr of therapy. At baseline, insulin-mediated glucose uptake was lower in hyperandrogenic women than in controls (by ANOVA, F = 14.3; P < 0.001). Insulin resistance was observed in both ovarian and nonovarian hyperandrogenism, as distinguished by acute GnRH agonist testing. After antiandrogen therapy, insulin action on glucose metabolism significantly increased for both the patients as a whole (F = 7.4; P < 0.01) and each treatment group separately. However, insulin action remained lower than in controls and showed no further improvement in patients reevaluated after I yr of treatment. Increases in both oxidative and nonoxidative glucose metabolism accounted for the improvement in substrate disposal induced by antiandrogen drugs. The increase in the effectiveness of insulin was greater in the lean subjects, whereas the change was small and not statistically significant in the obese women. Response to treatment was more pronounced in women with nonovarian hyperandrogenism, particularly at the low insulin infusion rate. Endogenous glucose production in hyperandrogenic patients was similar to that in healthy women and was unaffected by therapy. In conclusion, antiandrogen treatment partially reversed the peripheral insulin resistance associated with hyperandrogenism regardless of which antiandrogen was used. These data strongly suggest that in women, androgen excess per se contributes to impairment of insulin action.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8772557     DOI: 10.1210/jcem.81.3.8772557

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  46 in total

1.  Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile.

Authors:  E Zulian; P Sartorato; S Benedini; G Baro; D Armanini; F Mantero; C Scaroni
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

Review 2.  Aldosterone: a forgotten mediator of the relationship between psychological stress and heart disease.

Authors:  Laura D Kubzansky; Gail K Adler
Journal:  Neurosci Biobehav Rev       Date:  2009-07-22       Impact factor: 8.989

3.  Reversing the reduced level of endometrial GLUT4 expression in polycystic ovary syndrome: a mechanistic study of metformin action.

Authors:  Xin Li; Peng Cui; Hong-Yuan Jiang; Yan-Rong Guo; Bano Pishdari; Min Hu; Yi Feng; Håkan Billig; Ruijin Shao
Journal:  Am J Transl Res       Date:  2015-03-15       Impact factor: 4.060

Review 4.  How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome?

Authors:  E Diamanti-Kandarakis
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 5.  New routes in the polycystic ovary syndrome labyrinth: a way out?

Authors:  P Moghetti; R Castello
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 6.  Polycystic ovary syndrome: What is it? Pathogenetic enigma and therapeutic dilemma.

Authors:  V Toscano
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

7.  Testosterone Levels in Women: Implications for Fatty Liver and Beyond.

Authors:  Monika Sarkar
Journal:  J Womens Health (Larchmt)       Date:  2019-02-21       Impact factor: 2.681

8.  Hyperandrogenism Accompanies Increased Intra-Abdominal Fat Storage in Normal Weight Polycystic Ovary Syndrome Women.

Authors:  Daniel A Dumesic; Alin L Akopians; Vanessa K Madrigal; Emmanuel Ramirez; Daniel J Margolis; Manoj K Sarma; Albert M Thomas; Tristan R Grogan; Rasha Haykal; Tery A Schooler; Bette L Okeya; David H Abbott; Gregorio D Chazenbalk
Journal:  J Clin Endocrinol Metab       Date:  2016-08-29       Impact factor: 5.958

Review 9.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

10.  Effect of testosterone on insulin stimulated IRS1 Ser phosphorylation in primary rat myotubes--a potential model for PCOS-related insulin resistance.

Authors:  Michael C Allemand; Brian A Irving; Yan W Asmann; Katherine A Klaus; Laura Tatpati; Charles C Coddington; K Sreekumaran Nair
Journal:  PLoS One       Date:  2009-01-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.